Associated Papers
Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R et al.
Clinical and Experimental Medicine, 2023
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma.
Seidel MG et al.
Pediatric Blood & Cancer, 2023
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG et al.
Blood Advances, 2023
36083130 (PubMed )
Supplement: BLOODA_ADV-2022-007947-mmc1.pdf
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis.
Ozer E et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2019
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.
Yuan J et al.
Oncogene, 2018
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Nelson DS et al.
Genes, Chromosomes & Cancer, 2015
Somatic activating ARAF mutations in Langerhans cell histiocytosis.
Nelson DS et al.
Blood, 2014
Select a paper to view details